Gene Therapy and Antisense Drugs Market Expected to Be Biggest Emerging Market by 2025Medgadget (blog)Antisense gene therapy is emerging as one of the most beneficial therapeutics for various diseases such as tumors, cancer etc. These newer therapies a… Continue reading
Sci-Tech TodayBroad Institute Wins CRISPR Patent DecisionSci-Tech TodayHumans must become cyborgs if they are to stay relevant in a future dominated by artificial intelligence. That was the warning from Tesla founder Elon Musk, speaking at an event in … Continue reading
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track DesignationYahoo FinanceCell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announced the U.S. Food and Drug Administration (FDA) has gra… Continue reading
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track DesignationBusiness Wire (press release)LONDON & HOUSTON–(BUSINESS WIRE)–Cell Medica, a leader in developing cellular immunotherapy for the treatment of cancer, today announ… Continue reading
|
BrainStorm seeks early approval for stem cell treatment in Canada
Reuters TEL AVIV Israel’s BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials. |
|
BrainStorm seeks early approval for stem cell treatment in Canada
Yahoo Finance TEL AVIV, Feb 21 (Reuters) – Israel’s BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late … |
|
BrainStorm seeks early approval for stem cell treatment in Canada
Reuters TEL AVIV Israel’s BrainStorm Cell Therapeutics is seeking early approval in Canada for its adult stem cell treatment for patients with amyotrophic lateral sclerosis (ALS), a neuro-degenerative disease, even before it completes late-stage clinical trials. |
KIMT 3 |
Stem cells for osteoarthritis
KIMT 3 The one drawback is this therapy is not for patients whose arthritis is so bad it requires knee replacement surgery. Even though it’s still in the experimental stage, Dr. Yanke offers the stem cell treatment to his patients. But at a cost of $2,200 a … |